Articles From: Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Fragile X Syndrome to Alere Inc. Declares Cash Dividend on Its Series B Convertible Perpetual Preferred Stock


2014/8/11
Company Describes New Brain Imaging Data Supporting Use of MDX in ADHD Company Reviews Patients Demographics in Phase III study Conference Call & Webcast at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time TEL AVIV, Israel, Aug.
Sign-up for Alcobra Announces Second Quarter Financial Results and Provides Corporate Update investment picks
TEL AVIV, Israel, July 14, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd.
Sign-up for Alcobra Completes Patient Recruitment in Phase III Clinical Trial of MDX in Adult ADHD investment picks
TEL AVIV, Israel, July 17, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd.
Sign-up for Alcobra Discusses New Market Research and Updates on Recent Corporate Events at Investor Forum in New York City investment picks
TEL AVIV, Israel, Sept.
Sign-up for Alcobra Ltd. to Present at the Aegis Healthcare & Technology Conference investment picks
TEL AVIV, Israel, June 17, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd.
Sign-up for Alcobra Ltd. to Provide Corporate Overview at the JMP Securities Healthcare Conference investment picks
TEL AVIV, Israel, Aug.
Sign-up for Alcobra Releases New Neuroimaging Data Supporting Pro-Cognitive Effects of MDX investment picks
TEL AVIV, Israel, July 7, 2014 (GLOBE NEWSWIRE) -- Alcobra Ltd.
Sign-up for Alcobra to Host Investor Forum and Webcast on July 15 in New York City investment picks
BOTHELL, Wash., June 27, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., ("Alder") (Nasdaq:ALDR) , a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that Alder will be added to the Russell 3000® Index at the close of the market today, Friday, June 27, 2014 when Russell Investments reconstitutes its set of U.S. and global equity indexes.
Sign-up for Alder BioPharmaceuticals Added to Russell 3000(R) Index investment picks
Company Plans to Continue Development of Therapeutic Antibody for Autoimmune/Inflammatory Disease BOTHELL, Wash., Sept.
Sign-up for Alder BioPharmaceuticals Regains Worldwide Rights to Clazakizumab investment picks
BOTHELL, Wash., June 18, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR) , a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today provided recent corporate highlights and reported its financial results for the first quarter ended March 31, 2014.
Sign-up for Alder BioPharmaceuticals Reports First Quarter 2014 Financial Results investment picks
BOTHELL, Wash., Aug.
Sign-up for Alder BioPharmaceuticals Reports Second Quarter 2014 Financial and Operating Results investment picks
BOTHELL, Wash., July 29, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR) , a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that it will report its second quarter 2014 financial and operating results after the close of U.S. financial markets on Tuesday, August 5, 2014.
Sign-up for Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2014 Financial and Operating Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0959947001&sourceType=1 http://www.ccnmatthews.com/logos/20111003-advlogful.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Alderon Announces AGM Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0959660001&sourceType=1 http://www.ccnmatthews.com/logos/20111003-advlogful.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Alderon Announces Off-Take Transaction With Glencore investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0963879001&sourceType=1 http://www.ccnmatthews.com/logos/20111003-advlogful.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Alderon Provides Project Financing Update investment picks
BURLINGTON, Mass., June 19, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Stephen Tulipano has joined Aldeyra as its Chief Financial Officer, effective June 23, 2014.
Sign-up for Aldeyra Therapeutics Appoints Stephen Tulipano Chief Financial Officer investment picks
BURLINGTON, Mass., Sept.
Sign-up for Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials investment picks
BURLINGTON, Mass., Aug.
Sign-up for Aldeyra Therapeutics Reports Second Quarter 2014 Financial Results investment picks
BURLINGTON, Mass., July 23, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases thought to be related to free aldehydes, today announced that it will issue its financial results for the second quarter of 2014 on Monday, August 4, 2014, prior to the market open.
Sign-up for Aldeyra Therapeutics Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results investment picks
BURLINGTON, Mass., June 26, 2014 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, announced today that it will be added to the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2014, according to the preliminary list of additions announced via the Russell website on June 14, 2014.
Sign-up for Aldeyra Therapeutics to Join Russell Microcap Index investment picks
BURLINGTON, Mass., Sept.
Sign-up for Aldeyra Therapeutics to Present at Upcoming Investor Conferences investment picks
2014/8/27
By Ian Walker LONDON--Discount U.K. retailers Aldi and Lidl have maintained their record market shares as more shoppers flock to their stores, although both Asda and Waitrose have also seen their shares rise.
Sign-up for Aldi, Lidl, Asda, Waitrose Market Shares Rise investment picks
First Northern Community Bancorp (OTCQB:FNRN), holding company for First Northern Bank, announced that at the May 15, 2014, Organization Meeting of the Board of Directors of First Northern Community Bancorp and First Northern Bank, Lori J.
Sign-up for Aldrete Elected Vice Chairman of Board for First Northern Community Bancorp investment picks
Ron Zwanziger Resigns as Chief Executive Officer and President; Namal Nawana Appointed Interim CEO WALTHAM, Mass.
Sign-up for Alere Announces Management Transition investment picks
2014/7/1
By Michael Calia Alere Inc. said Tuesday that its chief executive and two other top executives resigned effective immediately as part of the health-care diagnostics company's strategic review.
Sign-up for Alere CEO, other top executives resign in overhaul investment picks
WALTHAM, Mass.
Sign-up for Alere Inc. Announces Second Quarter 2014 Results investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Alcobra Announces Enrollment of First Patient in Phase IIb Clinical Trial of MDX in Fragile X Syndrome to Alere Inc. Declares Cash Dividend on Its Series B Convertible Perpetual Preferred Stock
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices